Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom

A Markov model was used to assess the cost-effectiveness of ibrutinib compared with obinituzumab in combination with chlorambucil for untreated patients in the United Kingdom. The results showed ibrutinib not to be cost-effective. However, additional analyses showed ibrutinib to be significantly cost-effective compared with the current mode of care in which ibrutinib is administered as the second-line treatment.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research